您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 西班牙药房
产地国家: 西班牙
所属类别: 神经系统药物->抗抑郁药
处方药:处方药
包装规格: 100毫克/片 30片/盒
计价单位:
   
生产厂家英文名:
ANGELINI FARMACéUTICA S.A
该药品相关信息网址1:
http://www.igenericdrugs.com/gd.cgi?notran=1&s=Deprax&search=SEARCH
原产地英文商品名:
Deprax 100mg 30 tablets
原产地英文药品名:
Trazodone
中文参考商品译名:
Deprax 100毫克/片 30片/盒
中文参考药品译名:
曲唑酮
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
depression
英文适应病症2:
obsessive-compulsive disorder
临床试验期:
完成
中文适应病症参考翻译1:
抑郁症
中文适应病症参考翻译2:
强迫症
药品信息:
Deprax - Deprax (带舍曲林的总称)属于被称为选择性血清素再摄取抑制剂的药物组。这些选择性血清素再摄取药物影响的化学失衡负责抑郁症的大脑,恐慌焦虑,强迫症及其他。 Deprax是一种抗抑郁药,丙胺衍生物。其作用机制是与CNS中神经元的血清素再摄取的逆选择性阻断有关。氟西汀是胆碱,肾上腺素和组胺受体的弱拮抗剂。与大多数抗抑郁药氟西汀显然不会引起突触后降低β-肾上腺素能受体的功能活性。这种药物改善情绪,减轻焦虑和压力,消除烦躁不安。 Deprax不引起镇静作用。当您收到一个中等治疗剂量的这种药物不影响心血管等系统的功能。  主治:抑郁症,强迫症  主治:抑郁症,运动障碍,情绪障碍,术前用药,震颤 *有或无焦虑的临床抑郁症。 *失眠。 (在一些国家,这是一个关闭标签使用) *纤维肌痛,睡眠障碍提供帮助。 *恶梦或其他睡眠障碍的控制。  重性抑郁障碍的治疗,治疗强迫观念和强迫患者的强迫症(OCD )的;治疗惊恐障碍带或不带广场恐惧症,治疗创伤后应激障碍(PTSD )的治疗经前期烦躁不安的紊乱;治疗社交焦虑障碍(社交恐怖症) 。未标记UsesCholestatic瘙痒,潮热,夜间遗尿。 Deprax疼痛LABORATORIOS FARMACEUTICOS是一种抗抑郁药,丙胺衍生物。其作用机制是与CNS中神经元的血清素再摄取的逆选择性阻断有关。氟西汀是胆碱,肾上腺素和组胺受体的弱拮抗剂。与大多数抗抑郁药氟西汀显然不会引起突触后降低β-肾上腺素能受体的功能活性。这种药物改善情绪,减轻焦虑和压力,消除烦躁不安。 Deprax疼痛LABORATORIOS FARMACEUTICOS不引起镇静作用。当您收到一个中等治疗剂量的这种药物不影响心血管等系统的功能。  主治:抑郁症,强迫症,惊恐障碍,创伤后应激障碍 选择性血清素再摄取抑制剂用于: •急性和维持治疗的重度抑郁症( MDD)在8岁至18岁的成人和儿童患者年龄•急,在成人和儿童患者维持治疗强迫CompulsiveDisorder ( OCD)的7-17年•急性和成年患者维持治疗暴食症的•急性治疗惊恐障碍的,有或无广场恐怖症 Deprax - Deprax (with the generic name of Sertraline) belongs to the groups of drugs known as selective serotonin reuptake inhibitors. These selective serotonin reuptake drugs influence chemical imbalance in the brain responsible for depression, panic anxiety, obsessive compulsive disorder and others. Deprax is an antidepressant, propylamine derivative. The mechanism of action is associated with selective blockade of the inverse of neuronal serotonin reuptake in the CNS. Fluoxetine is a weak antagonist of choline, adrenergic and histamine receptors. Unlike most antidepressants fluoxetine apparently does not cause reduction of functional activity of postsynaptic beta-adrenergic receptors. This medication improves mood, reduces anxiety and stress, eliminates dysphoria. Deprax does not cause sedation. When you receive a medium therapeutic doses of this drug it does not affect the function of cardiovascular and other systems. Indications: depression, obsessive-compulsive disorder Indications: depression, dyskinesias, mood disorders, premedication, tremor * Clinical depression with or without anxiety. * Insomnia. (in some countries, this is an off-label use) * Fibromyalgia, to aid in sleeping. * Control of nightmares or other sleep disturbances. Treatment of major depressive disorder; treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD); treatment of panic disorder with or without agoraphobia; treatment of posttraumatic stress disorder (PTSD); treatment of premenstrual dysphoric disorder; treatment of social anxiety disorder (social phobia).Unlabeled UsesCholestatic pruritus, hot flashes, nocturnal enuresis. Deprax Ache Laboratorios Farmaceuticos is an antidepressant, propylamine derivative. The mechanism of action is associated with selective blockade of the inverse of neuronal serotonin reuptake in the CNS. Fluoxetine is a weak antagonist of choline, adrenergic and histamine receptors. Unlike most antidepressants fluoxetine apparently does not cause reduction of functional activity of postsynaptic beta-adrenergic receptors. This medication improves mood, reduces anxiety and stress, eliminates dysphoria. Deprax Ache Laboratorios Farmaceuticos does not cause sedation. When you receive a medium therapeutic doses of this drug it does not affect the function of cardiovascular and other systems. Indications: depression, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder selective serotonin reuptake inhibitor indicated for:• Acute and maintenance treatment of Major Depressive Disorder (MDD)in adult and pediatric patients aged 8 to 18 years • Acute and maintenance treatment of Obsessive CompulsiveDisorder (OCD) in adult and pediatric patients aged 7-17 years • Acute and maintenance treatment of Bulimia Nervosa in adult patients• Acute treatment of Panic Disorder, with or without agoraphobia, in adultpatients
更新日期: 2013-10-21
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com